Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

in response to

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

dlee38

posted on Apr 05, 2022 12:51PM

"But, currently RVX is being tiraled in population with diabetes not heart failure. These are 2 diff. populations."

The point being is that in general as I understand it, people with diabetes will die from some sort of heart disease, congestive heart failure (CHF) being one of them or at least being hospitalized for CHF. The standard of care for diabetes using Empagliflozin in combination with Apabetalone BOM clinical trial showed that there is a 41% Harazard Reduction with a P-Value of 0.03 in patients hospitalized suffering from Congestive Heart failure.